GlassScriptPhysician profile
Jeffrey B Crowder
NPI 1528063781
$12,703.76
in general payments reported to CMS, 2019-2025
30 companies · $4,596 in 2025
The $4,596 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $520 · 2021: $320 · 2022: $1,408 · 2023: $2,776 · 2024: $2,644 · 2025: $4,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,368 · Travel and Lodging: $1,006 · Consulting Fee: $400 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,367.93 |
| Travel and Lodging | $1,006.03 |
| Consulting Fee | $400.00 |
| Education | $241.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,828.32 | 2019-2025 | Clareon, Tryptyr, Hydrus Microstent |
| Biotissue Holdings INC. | $2,428.06 | 2022-2025 | |
| Glaukos Corporation | $1,184.14 | 2021-2025 | Idosetr, Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Lensar, INC. | $631.15 | 2023-2025 | Lensar Laser System |
| Sun Pharmaceutical Industries INC. | $525.81 | 2022-2025 | Cequa, Xelpros |
| Abbvie INC. | $503.98 | 2022-2025 | Durysta, Botox |
| Dompe US, INC. | $455.08 | 2023-2025 | Oxervate |
| Rxsight INC | $446.23 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Mallinckrodt Hospital Products INC. | $323.35 | 2022-2025 | Acthar |
| Rayner Intraocular Lenses Limited | $317.09 | 2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Emv |
| New World Medical,INC. | $311.92 | 2023-2025 | Streamline, Kahook Dual Blade, Via360 |
| Oyster Point Pharma, INC. | $289.80 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $261.45 | 2023-2025 | Miebo, Stellaris, Envista Envy Iol |
| Eyepoint US, INC. | $250.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $231.37 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $207.97 | 2022 | |
| Sight Sciences, INC. | $197.64 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Harrow Eye, LLC | $189.04 | 2024-2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $152.98 | 2022-2023 | Tecnis Iol, Tecnis Simplicity |
| Alimera Sciences, INC. | $127.49 | 2019 | |
| Ocular Therapeutix, INC. | $124.85 | 2022 | |
| Apellis Pharmaceuticals, INC. | $119.02 | 2023 | Syfovre |
| Tearlab Corp | $107.86 | 2023 | Tearlab Osmolarity System |
| Amgen INC. | $104.35 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $101.52 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $100.00 | 2024 | Acuvue |
| Astellas Pharma US INC | $74.82 | 2025 | Izervay |
| Galderma Laboratories, L.P. | $53.36 | 2021 | |
| Horizon Therapeutics Plc | $42.08 | 2023 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $13.03 | 2023 | Iolmaster 700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Crowder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.